ALK and non-small cell lung carcinoma: A recent study showed that a greater DepoR is associated with better clinical outcome in NSCLC patients receiving an anaplastic lymphoma kinase (ALK) inhibitor or a programed cell death-1 (PD-1) inhibitor5.